Go Pro
→ Ray Dalio: Buy Gold. Get Paid. (From Investors Alley) (Ad)tc pixel Free AMPE Stock Alerts

Ampio Pharmaceuticals (AMPE) Competitors

Ampio Pharmaceuticals logo
$0.18 0.00 (0.00%)
As of 07/10/2026
Compare

AMPE vs. HEPA, WINT, PTIX, LIPO, and BPTSY

Should you buy Ampio Pharmaceuticals stock or one of its competitors? MarketBeat compares Ampio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ampio Pharmaceuticals include Hepion Pharmaceuticals (HEPA), Windtree Therapeutics (WINT), Atrinsic (PTIX), Lipella Pharmaceuticals (LIPO), and Biophytis (BPTSY). These companies are all part of the "pharmaceutical products" industry.

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Hepion Pharmaceuticals Neutral

Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Hepion Pharmaceuticals N/A -812.56%-207.31%

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

Summary

Ampio Pharmaceuticals beats Hepion Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Ampio Pharmaceuticals Neutral

Windtree Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market.

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

Ampio Pharmaceuticals' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Ampio Pharmaceuticals N/A N/A N/A

Summary

Windtree Therapeutics and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Atrinsic?

Atrinsic (NASDAQ:PTIX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Atrinsic is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M-$3.45N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
Ampio Pharmaceuticals N/A N/A N/A

Atrinsic has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its share price is 496% more volatile than the broader market.

In the previous week, Atrinsic had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Atrinsic and 0 mentions for Ampio Pharmaceuticals. Atrinsic's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Atrinsic Neutral
Ampio Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Atrinsic beats Ampio Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Lipella Pharmaceuticals?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ampio Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Ampio Pharmaceuticals' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Ampio Pharmaceuticals N/A N/A N/A

Lipella Pharmaceuticals has higher revenue and earnings than Ampio Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.56-$5.02M-$2.42N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Ampio Pharmaceuticals Neutral

Lipella Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market.

Summary

Lipella Pharmaceuticals beats Ampio Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biophytis Neutral
Ampio Pharmaceuticals Neutral

Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Ampio Pharmaceuticals N/A N/A N/A

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPE vs. The Competition

Export
MetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$208K$776.41M$7.09B$23.47B
Dividend YieldN/A4.84%2.68%4.02%
P/E Ratio-0.021.6427.4231.40
Price / SalesN/A115.29528.3320.35
Price / CashN/A20.0648.4725.09
Price / Book0.058.4510.884.77
Net Income-$8.63M-$2.88M$3.59B$1.07B
7 Day PerformanceN/A-0.94%-0.26%-0.50%
1 Month PerformanceN/A2.05%4.55%0.06%
1 Year PerformanceN/A44.81%29.86%17.02%

Ampio Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat		N/AN/A$208KN/AN/A20
HEPA
Hepion Pharmaceuticals
N/A$0.06
-11.6%		N/A+0.0%$686KN/AN/A20
WINT
Windtree Therapeutics
N/A$0.01
+0.7%		N/A-97.8%$643KN/AN/A30
PTIX
Atrinsic
0.0345 of 5 stars		$0.35
-10.7%		N/A-93.0%$634KN/AN/A2
LIPO
Lipella Pharmaceuticals
N/A$0.13
+13.3%		N/A-91.3%$601K$536.36KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 7/12/2026 by MarketBeat.com Staff.
From Our Partners
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Sell Tesla, Buy the New King of FSD Cars
In 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel